Stockscreener 앱 받기
1.41
0.00%
0.00
시간 외 거래:
1.41
전일 마감가:
$1.41
열려 있는:
$1.4
하루 거래량:
1.62M
Relative Volume:
0.38
시가총액:
$461.52M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-5.2222
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+6.02%
1개월 성능:
-26.18%
6개월 성능:
+36.89%
1년 성능:
+100.65%
1일 변동 폭
$1.3901
$1.47
1주일 범위
$1.31
$1.475
52주 변동 폭
$0.515
$1.96
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.41 | 461.52M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
How cyclical is Ocugen Inc. (2H51) stock compared to rivalsMarket Sentiment Summary & Daily Entry Point Trade Alerts - mfd.ru
Is Ocugen Inc. stock attractive for ETFsJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
Aug EndMonth: Is Ocugen Inc a momentum stockJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
Stock Quote & Chart - Ocugen, Inc.
Highs Report: Is Ocugen Inc a cyclical or defensive stock2025 Retail Activity & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
What The Latest Developments Mean For Ocugen’s Changing Valuation Story - Yahoo Finance
Ocugen appoints Rita Johnson-Greene as chief financial officer - Pennsylvania Business Report -
Ocugen foresees gene-agnostic therapies advancing blindness treatment - Traders Union
Ocugen Bolsters Leadership Ahead of Critical Regulatory Milestone - AD HOC NEWS
Ocugen appoints Rita Johnson-Greene as new CFO By Investing.com - Investing.com South Africa
Ocugen appoints Rita Johnson-Greene as chief financial officer By Investing.com - Investing.com Canada
Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer - TipRanks
Ocugen (OCGN) Appoints New CFO, Shares Rise - GuruFocus
Ocugen (OCGN) Appoints New CFO to Strengthen Leadership Team - GuruFocus
Ocugen, Inc. Appoints New Chief Financial Officer - TradingView
Ocugen Names Rita Johnson-Greene as CFO - marketscreener.com
Ocugen appoints Rita Johnson-Greene as new CFO - Investing.com
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - citybiz
Ocugen, Inc. Appoints Rita Johnson-Greene as Chief Financial Officer - Quiver Quantitative
Ocugen Appoints Rita Johnson-Greene To Chief Financial Officer - TradingView
Cell and gene therapy exec Rita Johnson-Greene joins Ocugen as CFO - Stock Titan
Ocugen grants CEO new performance-based equity award - MSN
Wall Street Recap: Can Ocugen Inc be recession proof2025 Price Action Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Breakout Move: Will Ocugen Inc stock recover after earningsJuly 2025 Levels & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen’s Gene Therapy Progress and Funding Extend Runway - AD HOC NEWS
Ocugen Shares Stabilize Following Recent Equity Offering - AD HOC NEWS
Trade Report: Can Ocugen Inc be recession proofWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MSN
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
What are analysts price targets for Ocugen IncJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
Valuation Update: Can Belite Bio Inc Depositary Receipt deliver alphaWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
RSI Check: Can Ocugen Inc weather a recessionWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Ocugen’s Gene Therapy Candidate Shows Promise in Early-Stight Loss Trial - AD HOC NEWS
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial - NeurologyLive
Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial - CGTLive®
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 - MyChesCo
Macro Review: Is Ocugen Inc forming a double bottom2025 Volatility Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ocugen Stock: A Turnaround Fueled by Promising Trial Data - AD HOC NEWS
Ocugen’s Clinical Pipeline Takes Center Stage Following Capital Raise - AD HOC NEWS
How The Narrative Around Ocugen (OCGN) Is Shifting After The Latest Price Target Change - Yahoo Finance
Ocugen Secures Financial Runway Through Strategic Capital Raise - AD HOC NEWS
Ocugen Secures Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Ocugen Secures Funding at a Short-Term Cost to Shareholders - AD HOC NEWS
Ocugen Shares Defy Dilution Fears on Strong Clinical Data - AD HOC NEWS
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - Sahm
Ocugen closes $22.5 million registered direct offering By Investing.com - Investing.com South Africa
Ocugen Secures Financial Runway Through 2026 - AD HOC NEWS
How Fresh Capital And Positive OCU410 Data At Ocugen (OCGN) Has Changed Its Investment Story - Yahoo Finance
Ocugen strengthens balance sheet with new equity financing - TipRanks
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):